Revenue Cycle Analytics for Home Infusion Providers Managing Complex Therapy Mix
A small number of high-margin specialty patients can materially change a home infusion provider’s monthly revenue.
SolisRx builds the visibility to manage revenue volatility and protect what you’ve already earned.
SCHEDULE A CONSULTATIONHome Infusion Today
Home infusion therapy is a large infusion segment worth roughly $20 billion, and one of the most analytically demanding. A mid-sized provider manages hundreds of active patients, each with a distinct drug regimen, nursing schedule, prior authorization cycle, and payer relationship spanning Medicare and commercial.
Therapy economics are concentrated. IVIG and specialty biologics represent the highest-margin work and also the highest authorization complexity. A few dozen IVIG patients can account for a disproportionate share of the total margin of a home infusion operator.
The Visibility Gaps That Cost the Most
Authorization management is the highest-stakes monitoring problem. IVIG and specialty biologics authorizations specify therapy, duration, units, and approval windows. When care extends beyond the period or re-authorization is submitted late, the resulting denial is large and often unrecoverable.
Medicare Part B adds complexity: DMEPOS rules, nursing services benefit, and Part B versus Part D interactions create multi-layered billing where errors concentrate at intersections. Intake delays matter equally. A referral stalling in BIV for a week delays thousands of dollars in monthly contribution margin per IVIG patient.
How SolisRx Supports Home Infusion Providers
Revenue Cycle Analytics
Flag revenue leakage and protect cashflow
Authorization expiration monitoring across the full census- Denial analysis by CARC code and payer, focusing on Part B DMEPOS errors and prior authorization mismatches
- AR aging benchmarked by payer class
Learn More
Referral & Growth Intelligence
Focus sales effort for consistent revenue and growth
- Therapy mix analytics to monitor margin drivers and reduce volatility
- Physician-level referral attribution linked to revenue & gross margin outcomes + market share data
- Contribution margin by prescriber, therapy category and J-code
Learn More
Intake Optimization
Automate intake to shorten cycle times
- Referral-to-first-treatment pipeline tracker
- BIV, authorization, and nursing scheduling bottleneck identification
- Re-authorization tracking for chronic therapy patients
- Patient experience reporting to maintain care quality
Learn More
Executive Analytics
Make informed decisions with full organizational visibility
- Big picture view with KPI dashboards
- Double-click into site-level metrics and P&L
- Therapy mix trending, and payer concentration risk scoring
Learn More
Market Expansion
Base strategic decisions on in-depth expansion analytics
- Demand modeling
- Competitive landscape mapping
- Referral network analysis
- Payer mix profiling
Learn More
M&A Readiness
Stay diligence-ready with robust analytics infrastructure
- 36-month revenue trending
- Site-level EBITDA
- QoE data packages
- Data governance documentation
Learn More
Frequently Asked Questions
View More Resources
Why is our home infusion denial rate so high?
Denial patterns concentrate around three root causes: authorization mismatches (therapy administered differs from what was authorized or window expired), Medicare Part B DMEPOS billing errors, and commercial payer documentation failures. The root cause is almost always more concentrated than the aggregate denial rate suggests, and pulling claims, adjudication, and authorization data together into a cross-payer analysis reveals it.
What should our net collection rate be?
Top-quartile home infusion providers achieve above 95 percent of expected reimbursement. Mid-market averages significantly lower and the gap is almost entirely denial rates and AR write-offs, both reducible through structured exception analytics.
How do I track authorization status across all patients?
Manual tracking across a large census is the highest-risk operational gap in the industry. An automated monitoring system pulling authorization data, cross-referencing scheduled encounters and therapy parameters, and surfacing exceptions by urgency and dollar value is the most reliable approach.
What exactly does Stategis deliver?
We deliver tailored strategy, financial modeling, tech audits, and growth planning—backed by real execution support, not just recommendations.
What kind of companies do you typically work with?
We partner with venture-backed startups, scaling tech firms, consulting groups, and finance teams—from pre-seed to Series C and beyond.
Do you offer one-off projects or ongoing advisory?
Both. We offer focused sprints for immediate needs and retainer-based or embedded advisory for longer-term transformation.
How long does it take to get started?
We typically begin within 5–7 business days of your initial call, depending on scope and availability.
Is Stategis a good fit for early-stage startups?
Yes—especially if you’re preparing to raise capital, need a financial model, or want clear systems and priorities before scaling.
What industries do you specialize in?
Our core focus areas are SaaS, fintech, consulting, B2B services, and investment-backed ventures—but we’re flexible if there’s a strategic fit.
How long does it take to get started?
We typically begin within 5–7 business days of your initial call, depending on scope and availability.
What kind of companies do you typically work with?
We partner with venture-backed startups, scaling tech firms, consulting groups, and finance teams—from pre-seed to Series C and beyond.
What exactly does Stategis deliver?
We deliver tailored strategy, financial modeling, tech audits, and growth planning—backed by real execution support, not just recommendations.
Do you offer one-off projects or ongoing advisory?
Both. We offer focused sprints for immediate needs and retainer-based or embedded advisory for longer-term transformation.
Is Stategis a good fit for early-stage startups?
Yes—especially if you’re preparing to raise capital, need a financial model, or want clear systems and priorities before scaling.
What industries do you specialize in?
Our core focus areas are SaaS, fintech, consulting, B2B services, and investment-backed ventures—but we’re flexible if there’s a strategic fit.